周学敏,吕慧,朱国斌

• 1:山西医科大学第二医院心内科

摘要(Abstract)：

<正>1977年Gruentzig~[1]首先施行了经皮冠状动脉腔内成形术(percutaneous transluminal coronary angioplasty,PTCA),标志着冠状动脉介入治疗的诞生。PTCA被称为经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的第一次革命。而PTCA主要问题是术后再狭窄率高。由于早期血管弹性回缩、晚期血管负性重塑及新生内膜过度增生等因素,单纯球囊扩张术后再狭窄率高达30%~50%~[2]。20世纪90年代,裸金属支架(bare metal stents,BMS)的出现克服

关键词(KeyWords)： 生物可吸收支架;经皮冠状动脉介入治疗;裸金属支架;药物洗脱支架

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周学敏,吕慧,朱国斌

参考文献(References)：

• [1]Gruntzig A.Transluminal dilatation of coronary-artery stenosis.Lancet,1978,1:263.
• [2]高润霖.药物洗脱支架研究现状及进展.中国实用内科杂志,2006,15:1121-1123.
• [3]Hoffmann R,Mintz GS,Dussaillant GR,et al.Patterns and mechanisms of in-stent restenosis.A serial intravascular ultrasound study.Circulation,1996,94:1247-1254.
• [4]Lagerqvist B,James SK,Stenestrand U,et al.Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.N Engl J Med,2007,356:1009-1019.
• [5]周玉杰.心血管介入治疗的新思路和新技术.心血管病学进展,2012,33:685-687.
• [6]Serruys PW,Onuma Y,Dudek D,et al.Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis:12-month clinical and imaging outcomes.J Am Coll Cardiol,2011,58:1578-1588.
• [7]Onuma Y,Dudek D,Thuesen L,et al.Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease:the ABSORB cohort A trial.JACC Cardiovasc Interv,2013,6:999-1009.
• [8]Serruys PW,Onuma Y,Garcia-Garcia HM,et al.Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold:a multiimaging modality study at 6,12,24 and 36 months.Euro Intervention,2014,9:1271-1284.
• [9]Verheye S,Ormiston JA,Stewart J,et al.A next-generation bioresorbable coronary scaffold system:from bench to first clinical evaluation:6-and 12-month clinical and multimodality imaging results.JACC Cardiovasc Interv,2014,7:89-99.
• [10]Onuma Y,Ormiston J,Serruys PW.Bioresorbable scaffold technologies.Circ J,2011,75:509-520.
• [11]Tamai H,Igaki K,Kyo E,et al.Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.Circulation,2000,102:399-404.
• [12]Erbel R,Di Mario C,Bartunek J,et al.Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents:a prospective,non-randomised multicentre trial.Lancet,2007,369:1869-1875.
• [13]Stack RS,Califf RM,Phillips HR,et al.Interventional cardiac catheterization at Duke Medical Center.Am J Cardiol,1988,62:3F-24F.
• [14]Ormiston JA,Serruys PW,Regar E,et al.A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions(ABSORB):a prospective openlabel trial.Lancet,2008,371:899-907.
• [15]Serruys PW,Ormiston JA,Onuma Y,et al.A bioabsorbable everolimus-eluting coronary stent system(ABSORB):2-year outcomes and results from multiple imaging methods.Lancet,2009,373:897-910.
• [16]Onuma Y,Dudek D,Thuesen L,et al.Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease:the ABSORB cohort A trial.JACC Cardiovasc Interv,2013,6:999-1009.
• [17]Abizaid A,Ribamar CJJ,Bartorelli AL,et al.The ABSORB EXTEND study:preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled.Euro Intervention,2015,10:1396-1401.
• [18]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORBⅡ):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385:43-54.
• [19]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385:43-54.
• [20]Dudek D,Rzeszutko L,Zasada W,et al.Bioresorbable vascular scaffolds in patients with acute coronary syndromes:the POLAR ACS study.Pol Arch Med Wewn,2014,124:669-677.
• [21]Everaert B,Felix C,Koolen J,et al.Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions:a recommendation from experienced users.Netherlands Heart Journal,2015,23:161-165.
• [22]Allahwala UK,Cockburn JA,Shaw E,et al.Clinical utility of optical coherence tomography(OCT)in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.Euro Intervention,2015,10:1154-1159.
• [23]Wijns W,Kolh P,Danchin N,et al.Guidelines on myocardial revascularization.Eur Heart J,2010,31:2501-2555.
• [24]Colombo A,Chieffo A,Frasheri A,et al.Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy:the SECURITY randomized clinical trial.J Am Coll Cardiol,2014,64:2086-2097.
• [25]肖国胜,王焱,叶涛,等.完全生物可降解支架置入术及术后18月随访一例.中国介入心脏病学杂志,2014,22:673-674.
• [26]Sato K,Panoulas VF,Naganuma T,et al.Optimal duration of dual antiplatelet therapy after implantation of bioresorbable vascular scaffolds:lessons from optical coherence tomography.Can J Cardiol,2014,30:1415-1460.
• [27]Wiebe J,Nef HM,Hamm CW.Current status of bioresorbable scaffolds in the treatment of coronary artery disease.J Am Coll Cardiol,2014,64:2541-2551.
• [28]Felix C,Everaert B,Diletti R,et al.Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.Neth Heart J,2015,23:153-160.
• [29]周力,孙颖,陈晖.全吸收式生物可降解支架在冠心病介入治疗中的应用.中国介入心脏病学杂志,2014,22:262-264.